Abstract
The first human administration of a new thebaine derivative is described. The drug elicited visual imagery with eyes closed, synaesthesiae and hallucinatory phenomena. In addition to these “psychotomimetic” effects dysphoria, estrangement, withdrawal and some confusional trends were noted. Physical effects such as tinnitus, ptosis, slurred speech, ataxia, perspiring, “tingling” of the skin, increase in deep tendon reflexes and variable effects on blood pressure were noted. These effects were of long duration and were elicited by doses of the drug as low as 1 Μg/kg. The possible significance of the extraordinary potency of this compound is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blane, G. F., Boura, A. L. A., Fitzgerald, A. E., Lister, R. E.: Actions of etorphine hydrochloride (M-99) a potent morphine-like agent. Brit. J. Pharmacol. Chemother. 30, 11 (1967).
Eddy, N. B., Martin, W. R.: Drug dependence of specific opiate antagonist type. Pharmakopsychiat. Neuro-Psychopharmak. 3, 73 (1970).
Jasinski, D. R., Martin, W. R., Sapira, J. D.: Antagonism of the subjective, behavioral, pupillary and respiratory depressant effects of cyclazocine by naloxone. Clin. Pharmacol. Ther. 9, 215–229 (1968).
Martin, W. R.: Opioid antagonists. Phamacol. Rev. 19, 463–521 (1967).
Preclinical Trial Brochure, Cl 110,393, Analgesic Agent. Lederle Laboratories, American Cyanamid Company, Pearl River, New York.
Resnick, R. B., Fink, M., Freedman, A. M.: Cyclazocine treatment of opiate dependence: A progress report. Comp. Psychiat. 12, 491–502 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Angrist, B., Gershon, S. Behavioral profile of a potent new psychotoxic compound. Psychopharmacologia 30, 109–116 (1973). https://doi.org/10.1007/BF00421425
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00421425